|
||||||||||||||||||||
|
||||||||||||||
Bausch & Lomb/BullsWe don't have a Bulls article about Bausch & Lomb/Bulls yet. You could be the first person to write a bullish analysis about Bausch & Lomb/Bulls. As the first editor, you could earn a "Top Contributor" spot if you have an account. Top 3 Bulls Arguments
With almost 60% of revenue from overseas, Bausch & Lomb's geographically diversified sales shields it from regional market fluctuations. Bausch's PureVision line of silicone hydrogel contact lenses has shown solid double-digit growth, due to the shifting consumer trend toward the newer technology. PureVision has only one competitor its market, and is the only 30-day extended wear lens currently available to treat astigmatism and presbyopia. Bausch holds dominant share in the rapidly growing market of ocular vitamins, which have been shown to be effective in lowering the risk of age-related macular degeneration. |
The Shelf
|